Comparative Pharmacology
Head-to-head clinical analysis: GASTROMARK versus OMNIPAQUE 12.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROMARK versus OMNIPAQUE 12.
GASTROMARK vs OMNIPAQUE 12
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gastromark (ferumoxsil) is an oral superparamagnetic contrast agent used in MRI. It contains iron oxide particles that create local magnetic field inhomogeneities, reducing T2* signal in the gastrointestinal tract, thereby improving visualization of abdominal organs by darkening the bowel lumen.
Radiopaque agent that attenuates X-rays, providing contrast in imaging. Iodine atoms absorb X-rays, enhancing visualization of blood vessels and tissues.
Orally, 30-60 mL of a 1% suspension (300-600 mg iron) diluted in water or juice, given 12-24 hours prior to MRI examination; may be repeated if necessary.
Adult dose: 12 g iodine (e.g., 200 mL of Omnipaque 12) administered intravenously, intra-arterially, or into body cavities. Typical contrast study dose: 1-2 mL/kg (max 150 mL) for CT; 40-60 mL for angiographic procedures.
None Documented
None Documented
Terminal elimination half-life: 3.1-3.5 hours; clinical context: supports rapid clearance from the body after imaging.
1-2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 23-31% as intact compound; fecal: 69-77% via biliary elimination; very little metabolism.
Renal: >95% unchanged; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent